USFDA Concludes Surprise Audit at Alembic Pharma’s Vadodara Site with Zero Form 483 Observations
Pharm'Up 
Alembic Pharmaceuticals Limited has cleared an unannounced regulatory audit conducted by the United States Food and Drug Administration (USFDA) at its bioequivalence facility in Vadodara, Gujarat, with no Form 483 observations issued.
The onsite assessment, which ran from August 31 to September 10, 2026, evaluated the facility’s bioequivalence workflows and compliance standards. The issuance of zero Form 483 observations indicates that federal investigators flagged no regulatory violations, operational deficiencies, or objectionable conditions during their review.
Alembic’s Vadodara unit executes pivotal comparative studies to establish that generic candidates match the performance and bioavailability of reference listed drugs (RLDs). Successful completion of the unannounced audit reaffirms the site’s alignment with international quality standards, robust clinical oversight, and strict data integrity requirements necessary for US market filings. The company has formally reported the audit outcome to domestic stock exchanges.
About the Author
